MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

243.19
-4.53
-1.83%
After Hours: 245.25 +2.06 +0.85% 19:38 09/21 EDT
OPEN
247.04
PREV CLOSE
247.72
HIGH
247.04
LOW
238.20
VOLUME
2.75M
TURNOVER
--
52 WEEK HIGH
264.97
52 WEEK LOW
177.05
MARKET CAP
142.43B
P/E (TTM)
19.87
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eli Lilly CEO: Speed and industry cooperation are aiding coronavirus treatment development
"We developed this antibody and got to proof of concept in six months. Usually, that's more than six years," Eli Lilly CEO Ricks said on CNBC's "Mad Money."
CNBC.com · 7h ago
Baird makes a negative outlier, losing enthusiasm for this cancer fighter
A research update still has Baird bucking a generally Bullish Wall Street on Amgen (AMGN), as the firm notes enthusiasm is "waning" over the size of the company's KRAS G12C
Seekingalpha · 8h ago
Anticancer Drug Team-Ups Show Promise. 4 Stocks That Stand to Gain.
Some of the best news at the European Society for Medical Oncology conference was for breast-cancer patients.
Barrons.com · 15h ago
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Zacks · 18h ago
The 5 Undervalued Blue Chip High Dividend Growth Stocks You Need To Buy Now
The core of a dividend portfolio should be made of all weather dividend stocks.Buying these stocks when they are undervalued is important if you want great performance.It is once again difficult to find value, but it can be found in every market.You just need to be willing to look.
Seekingalpha · 1d ago
Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors, were published in the New England Journal of Medicine (NEJM). Data from 59 patients
PR Newswire · 1d ago
Amgen Reports Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In NEJM Confirmed and Durable Anticancer Activity in Heavily Pretreated Non-Small Cell Lung Cancer
Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors, were published in the New England Journal of Medicine (NEJM).
Benzinga · 1d ago
Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study
Reuters · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 29 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMGN stock price target is 262.76 with a high estimate of 308.00 and a low estimate of 185.00.
EPS
Institutional Holdings
Institutions: 2.57K
Institutional Holdings: 475.60M
% Owned: 81.20%
Shares Outstanding: 585.69M
TypeInstitutionsShares
Increased
757
23.31M
New
240
-1.01M
Decreased
817
22.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.98%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President/Chief Compliance Officer
Cynthia Patton
Senior Vice President/General Counsel/Secretary
Jonathan Graham
Senior Vice President/Director of Human Resources
Lori Johnston
Senior Vice President
David Piacquad
Chief Accounting Officer/Vice President - Finance
Linda Louie
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Fred Hassan
Independent Director
Charles Holley
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
R. Sanders Williams
Independent Director
Robert Williams
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/23/2020
Dividend USD 1.6
08/14/2020
03/04/2020
Dividend USD 1.6
05/15/2020
12/11/2019
Dividend USD 1.6
02/13/2020
10/22/2019
Dividend USD 1.45
11/14/2019
08/02/2019
Dividend USD 1.45
08/14/2019
03/07/2019
Dividend USD 1.45
05/16/2019
12/07/2018
Dividend USD 1.45
02/14/2019
10/23/2018
Dividend USD 1.32
11/15/2018
07/31/2018
Dividend USD 1.32
08/16/2018
03/07/2018
Dividend USD 1.32
05/16/2018
12/12/2017
Dividend USD 1.32
02/14/2018
10/24/2017
Dividend USD 1.15
11/16/2017
07/28/2017
Dividend USD 1.15
08/15/2017
03/07/2017
Dividend USD 1.15
05/15/2017
12/20/2016
Dividend USD 1.15
02/13/2017
10/14/2016
Dividend USD 1
11/14/2016
07/22/2016
Dividend USD 1
08/15/2016
03/02/2016
Dividend USD 1
05/13/2016
12/15/2015
Dividend USD 1
02/11/2016
10/14/2015
Dividend USD 0.79
11/12/2015
07/28/2015
Dividend USD 0.79
08/13/2015
03/04/2015
Dividend USD 0.79
05/12/2015
12/17/2014
Dividend USD 0.79
02/10/2015
10/17/2014
Dividend USD 0.61
11/10/2014
07/25/2014
Dividend USD 0.61
08/12/2014
03/05/2014
Dividend USD 0.61
05/13/2014
12/13/2013
Dividend USD 0.61
02/11/2014
10/16/2013
Dividend USD 0.47
11/12/2013
07/26/2013
Dividend USD 0.47
08/14/2013
03/06/2013
Dividend USD 0.47
05/14/2013
12/13/2012
Dividend USD 0.47
02/11/2013
10/10/2012
Dividend USD 0.36
11/13/2012
07/19/2012
Dividend USD 0.36
08/14/2012
03/15/2012
Dividend USD 0.36
05/14/2012
12/15/2011
Dividend USD 0.36
02/13/2012
10/13/2011
Dividend USD 0.28
11/15/2011
07/28/2011
Dividend USD 0.28
08/16/2011

Analyst Price Target

The average AMGN stock price target is 262.76 with a high estimate of 308.00 and a low estimate of 185.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.